®

MKT155 2.0

®

info@perspectum.com | perspectum.com | US: (+1) 972 803 5501 | UK: (+44) 1865 655325

Introducing LiverMultiScan

In a single, non-invasive MRI examination, LiverMultiScan® characterizes liver tissue by providing three key metrics—PDFF, T2* and cT1. These have been shown to correlate with liver fat1,2, iron content3,4,5 and fibro-inflammation6,7 respectively.

Clinicians will receive reports that include these quantitative metrics to support the diagnosis ofliver disorders as inputs forming part of a wider diagnostic process.

LiverMultiScan provides measures that can be used to assess a wide variety of liver disorders

Diagnosis of liver disease relies on a range of pathological features. Currently available tests do not capture all aspects of disease progression. LiverMultiScan enables the comprehensive assessment of the liver parenchyma.

Healthy Liver

Fatty Liver

Inflamed Liver

FibroticLiver

CirrhoticLiver

ULTRASOUNDELASTOGRAPHY

LiverMultiScan provides quantitative metrics for liver tissue characterization

Healthy PatientNASH Patient

cT1: 950msReference range: 633-794ms

T2*: 15.3msNormal range: >12.5ms at 3T

PDFF: 22.5%Normal range: <5.6%

cT1: 645msReference range: 633-794ms

T2*: 18.2msNormal range: >12.5ms at 3T

PDFF: 1.8%Normal range: <5.6%

cT1T2*PDFFcT1T2*PDFF

®

MKT155 2.0

®

info@perspectum.com | perspectum.com | US: (+1) 972 803 5501 | UK: (+44) 1865 655325

Introducing LiverMultiScan

In a single, non-invasive MRI examination, LiverMultiScan® characterizes liver tissue by providing three key metrics—PDFF, T2* and cT1. These have been shown to correlate with liver fat1,2, iron content3,4,5 and fibro-inflammation6,7 respectively.

Clinicians will receive reports that include these quantitative metrics to support the diagnosis ofliver disorders as inputs forming part of a wider diagnostic process.

LiverMultiScan provides measures that can be used to assess a wide variety of liver disorders

Diagnosis of liver disease relies on a range of pathological features. Currently available tests do not capture all aspects of disease progression. LiverMultiScan enables the comprehensive assessment of the liver parenchyma.

Healthy Liver

Fatty Liver

Inflamed Liver

FibroticLiver

CirrhoticLiver

ULTRASOUND ELASTOGRAPHY

LiverMultiScan provides quantitative metrics for liver tissue characterization

Healthy Patient NASH Patient

cT1: 950msReference range: 633-794ms

T2*: 15.3msNormal range: >12.5ms at 3T

PDFF: 22.5%Normal range: <5.6%

cT1: 645msReference range: 633-794ms

T2*: 18.2msNormal range: >12.5ms at 3T

PDFF: 1.8%Normal range: <5.6%

cT1 T2* PDFF cT1 T2* PDFF

®

MKT155 2.0

®

info@perspectum.com | perspectum.com | US: (+1) 972 803 5501 | UK: (+44) 1865 655325

FAQ’S

How long is the scan and is it longer than a normal MRE or MRI-PDFF? LiverMultiScan includes three measures—PDFF, T2* and cT1. The total acquisition time in the MRI scanner is less than 7 minutes and the entire procedure lasts up to 15 minutes (includes time for patient preparation). LiverMultiScan is not substantially longer than a normal MRE or MRI-PDFF examination which provides information for one measure only.

Can you scan just the liver and not the other parts of the abdomen?The procedure requires the abdomen to be scanned to ensure complete coverage of the liver. Technicians will focus the field of view on the area to be scanned, but some of the tissue surrounding the liver may also be acquired in the scan. Although surrounding tissue will be imaged, metrics will only be quantified from the liver.

Does this add more cost to the patient and will it be approved by insurance?Reimbursement for an abdominal MRI may fall under clinical indications when there is evidence of advanced fibrosis, high-risk features or other clinical indications as determined by insurance providers.

Will this exam be useful for more than just NASH? The exam can be used as a diagnostic aid for the evaluation of many types of liver disorders.References1. Idilman, I.S., et al. (2013). Radiology, 267(3), 767-75. 2. Reeder, C., et al. (2017). Psychol Med, 47(15), 2720-30. 3. Wood, J.C., et al. (2007). Am J Hematol, 82(12), 1132-5. 4. Chandarana, H., et al. (2009). AJR Am J Roentgenol, 193(5), 1550-7. 5. Ganne-Carrie, N., et al. (2000). Gut, 46(2), 277-82. 6. Banerjee, R., et al. (2014). J Hepatol, 60(1), 69-77. 7. Pavlides, M., et al. (2016). J Hepatol, 64(2), 308-15. 8. Chalasani, N., et al. (2018). Hepatology, 67(1), 328-57. 9. Jayaswal, A.N., et al. (2019). DDW, May 18-21, San Diego, 156(6), S-1325. 10. Harrison, S., et al. (2019). EASL, Apr 10-14, Vienna, 70(1), e770.

LiverMultiScan is FDA 510(k) cleared. The metrics reported by LiverMultiScan have undergone extensive verification and validation performance testing; however, use of the device for specific liver disorders has not been evaluated by the US FDA. LiverMultiScan has regulatory clearance in the following territories: US, EU, Hong Kong, Malaysia, Singapore, Australia and New Zealand.

Suspectedpatients

with NASH andadvanced

fibrosis

Elastography for liver stiffness

(undefined cut-off) Lifestyle intervention, follow-up for

monitoring

Liver biopsy

NASH treatment

High-risk Low-risk

Based on current AASLD guidance8With LiverMultiScan7,9,10

Transforming the NASH clinical work-flow

LiverMultiScan can be incorporated into the clinical work-flow as a diagnostic aid for patients with liver disorders or abnormalities. This is achieved through the non-invasive and highly-repeatable assessment of liver tissue.

Suspectedpatients

with NASH and advanced

fibrosis

Lifestyle intervention, follow-up for

monitoring

Low-risk: cT1 < 825 ms

NASH treatment

High-risk: cT1 ≥ 825 ms

®

MKT155 2.0

®

info@perspectum.com | perspectum.com | US: (+1) 972 803 5501 | UK: (+44) 1865 655325

FAQ’S

How long is the scan and is it longer than a normal MRE or MRI-PDFF? LiverMultiScan includes three measures—PDFF, T2* and cT1. The total acquisition time in the MRI scanner is less than 7 minutes and the entire procedure lasts up to 15 minutes (includes time for patient preparation). LiverMultiScan is not substantially longer than a normal MRE or MRI-PDFF examination which provides information for one measure only.

Can you scan just the liver and not the other parts of the abdomen?The procedure requires the abdomen to be scanned to ensure complete coverage of the liver. Technicians will focus the field of view on the area to be scanned, but some of the tissue surrounding the liver may also be acquired in the scan. Although surrounding tissue will be imaged, metrics will only be quantified from the liver.

Does this add more cost to the patient and will it be approved by insurance?Reimbursement for an abdominal MRI may fall under clinical indications when there is evidence of advanced fibrosis, high-risk features or other clinical indications as determined by insurance providers.

Will this exam be useful for more than just NASH? The exam can be used as a diagnostic aid for the evaluation of many types of liver disorders.References1. Idilman, I.S., et al. (2013). Radiology, 267(3), 767-75. 2. Reeder, C., et al. (2017). Psychol Med, 47(15), 2720-30. 3. Wood, J.C., et al. (2007). Am J Hematol, 82(12), 1132-5. 4. Chandarana, H., et al. (2009). AJR Am J Roentgenol, 193(5), 1550-7. 5. Ganne-Carrie, N., et al. (2000). Gut, 46(2), 277-82. 6. Banerjee, R., et al. (2014). J Hepatol, 60(1), 69-77. 7. Pavlides, M., et al. (2016). J Hepatol, 64(2), 308-15. 8. Chalasani, N., et al. (2018). Hepatology, 67(1), 328-57. 9. Jayaswal, A.N., et al. (2019). DDW, May 18-21, San Diego, 156(6), S-1325. 10. Harrison, S., et al. (2019). EASL, Apr 10-14, Vienna, 70(1), e770.

LiverMultiScan is FDA 510(k) cleared. The metrics reported by LiverMultiScan have undergone extensive verification and validation performance testing; however, use of the device for specific liver disorders has not been evaluated by the US FDA. LiverMultiScan has regulatory clearance in the following territories: US, EU, Hong Kong, Malaysia, Singapore, Australia and New Zealand.

Suspectedpatients

with NASH andadvanced

fibrosis

Elastography for liver stiffness

(undefined cut-off)Lifestyle intervention, follow-up for monitoring

Liver biopsy

NASH treatment

High-riskLow-risk

Based on current AASLD guidance8 With LiverMultiScan7,9,10

Transforming the NASH clinical work-flow

LiverMultiScan can be incorporated into the clinical work-flow as a diagnostic aid for patients with liver disorders or abnormalities. This is achieved through the non-invasive and highly-repeatable assessment of liver tissue.

Suspectedpatients

with NASH and advanced

fibrosis

Lifestyle intervention, follow-up for monitoring

Low-risk: cT1 < 825 ms

NASH treatment

High-risk: cT1 ≥ 825 ms